Literature DB >> 2894958

Metabolism of bepridil in laboratory animals and humans.

W N Wu1, J F Hills, S Y Chang, K T Ng.   

Abstract

The metabolism of bepridil was studied in the Swiss mouse, Sprague-Dawley rat, New Zealand rabbit, rhesus monkey, and healthy human. After oral administration of bepridil-14C-hydrochloride, recoveries of total radioactivity in urine and feces (7 days) were greater than or equal to 80% of the administered dose in all five species. Bepridil and 25 metabolites have been isolated by HPLC and TLC from representative plasma, urine, and fecal extract pools from all species and identified on the basis of TLC, HPLC, and mass spectrometry. The identified metabolites explained 60-99% of the total radioactivity in each sample for rabbit plasma, in which only 17% of the total radioactivity was characterized. Metabolic pathways involving oxidative reactions at seven sites on the bepridil molecule are proposed for each species. Metabolite formation in the five species is described by four interrelated pathways. The metabolic pathway involving aromatic hydroxylation followed by N-dealkylation, N-debenzylation, and N-acetylation was important in all species. Major metabolites produced by this pathway included 4-hydroxy(at N-phenyl)-bepridil (Ia), N-benzyl-4-amino-phenol (IV), and N-acetyl-4-aminophenol (Vy). Metabolite Ia was isolated in significant amounts (greater than or equal to 5% of sample) in all fecal and urine samples except rat urine. Metabolite IV was a major circulating metabolite in all species and a major urinary metabolite in humans. Metabolite Vy was present in significant quantities in urine in all species except rabbit. Other important pathways involved primary reactions such as iso-butyl hydroxylation, pyrrolidine ring oxidation, and N-debenzylation.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2894958

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  3 in total

1.  Comparative study of the biotransformation of bepridil analogs in isolated liver cells from one rat. Relationships between structure and in vitro liver toxicity.

Authors:  E Damatte; M J Galmier; C Lartigue-Mattei; J F Pognat; N Busch; J L Chabard
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Oct-Dec       Impact factor: 2.441

Review 2.  Bepridil. A review of its pharmacological properties and therapeutic use in stable angina pectoris.

Authors:  L M Hollingshead; D Faulds; A Fitton
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

3.  Evaluation of the absorption, excretion, and metabolism of the antihypertensive agent RWJ-26899 in male and female CR Wistar rats and Beagle dogs.

Authors:  W N Wu; G W Caldwell; J A Masucci
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2001 Jul-Sep       Impact factor: 2.569

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.